Navelbine (Vinorelbine)

Vinorelbine, the active ingredient in Navelbine, is a Vinca alkaloid presented as an oral capsule for oral use. It treats certain adult cancers, specifically non‑small cell lung cancer and breast cancer, by interfering with cell division. GNH USA supplies Navelbine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Vinorelbine is employed in oncology protocols targeting malignant growth pathways. - Non‑small cell lung cancer: improves disease control and may extend survival when used in combination chemotherapy. - Breast cancer: incorporated into regimens for metastatic or advanced disease to inhibit tumor proliferation. - Combination therapy: enhances the efficacy of other antineoplastic agents in multi‑drug protocols.

Vinorelbine may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Neutropenia - Constipation - Fatigue - Alopecia - Mild liver enzyme elevation

Serious or Rare Side Effects: - Severe neutropenia or febrile neutropenia - Pulmonary toxicity (e.g., interstitial pneumonitis) - Peripheral neuropathy - Severe allergic reactions (anaphylaxis) - Significant liver dysfunction - Cardiac arrhythmias or QT prolongation

Vinorelbine requires careful monitoring and specific safety measures before and during therapy. - Monitor blood counts: perform regular complete blood count assessments to detect neutropenia. - Assess liver function: conduct periodic liver enzyme tests to identify hepatotoxicity. - Evaluate pulmonary status: watch for new or worsening respiratory symptoms. - Avoid use in severe renal impairment: adjust therapy only under specialist guidance. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Vinorelbine can interact with other medicines, influencing its safety and effectiveness.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase vinorelbine toxicity. - Potent CYP3A4 inducers (e.g., rifampicin) may reduce therapeutic exposure. - Concurrent myelosuppressive agents can cause severe bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Antiemetics with CYP3A4 activity (e.g., ondansetron) may alter plasma levels. - Anticoagulants may heighten bleeding risk when combined with vinorelbine. - Drugs that prolong QT interval require ECG monitoring during combined use.